001360.Ks

The company's capital structure is characterized by a relatively low debt-to-equity ratio of 0.15, indicating a conservative leverage position compared to industry norms. However, the company's liquidity is assessed as medium, with a current ratio of 0.92, suggesting that it may face challenges in meeting short-term obligations without additional financing. The company's cash and equivalents amount to 11,165,831,070 KRW, but this is offset by long-term debt of 17,698,273,440 KRW, resulting in a net cash position that is negative.

Profitability metrics show a mixed picture. The company reported a net income of 11,545,101,570 KRW, but this was achieved despite an operating loss of 20,627,369,610 KRW, indicating significant non-operating income or gains. The return on equity (ROE) is 9.54%, and the return on assets (ROA) is 6.9%, both of which are below the industry median for pharmaceutical companies, suggesting that the company is underperforming in terms of asset utilization and shareholder returns.

The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases the company's exposure to regional economic fluctuations and regulatory changes. The absence of segment or geographic breakdown in the financial data limits the ability to assess the company's risk profile in detail.

The company's growth trajectory is uncertain, with no clear indication of revenue growth in the current fiscal year. The operating cash flow is negative at -10,050,871,540 KRW, and the free cash flow is only 220,775,570 KRW, which is insufficient to fund capital expenditures of 12,763,600,000 KRW. This suggests that the company may need to rely on external financing to maintain its operations and invest in future growth.

The company's risk assessment highlights a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt indicates potential liquidity constraints. The dilution risk is low, with no significant dilution potential in the basic shares outstanding, and no recent adjustments to the valuation that would suggest a need for equity financing.

Recent events, as reflected in the financial data, include a significant operating loss and a negative operating cash flow. These indicators suggest that the company is facing operational challenges, which may be related to increased costs, reduced sales, or other factors affecting its profitability. The absence of recent filings or transcripts limits the ability to assess the company's strategic direction and management's response to these challenges.